We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Rapid, Direct-to-Digital Prostate Biopsy Pathology Evaluated

By LabMedica International staff writers
Posted on 13 May 2021
Print article
Image: Standard hematoxylin-eosin sections are unaffected by processing and imaging by clearing histology with multiphoton microscopy (CHiMP). Portions of the same core biopsy were submitted directly to standard processing (A) or processed by CHiMP and subsequently embedded in paraffin, sectioned, and stained (B), showing equivalent coloration and morphology (Photo courtesy of Yale School of Medicine)
Image: Standard hematoxylin-eosin sections are unaffected by processing and imaging by clearing histology with multiphoton microscopy (CHiMP). Portions of the same core biopsy were submitted directly to standard processing (A) or processed by CHiMP and subsequently embedded in paraffin, sectioned, and stained (B), showing equivalent coloration and morphology (Photo courtesy of Yale School of Medicine)
Increasing adoption of digital pathology promises marked improvements in reproducibility, efficiency, and accuracy of tissue-based diagnostics by facilitating routine remote expert consultation and enabling computerized image analysis for clinical use.

Clearing histology with multiphoton microscopy (CHiMP) is a new technique for tissue processing and image acquisition that eliminates conventional paraffin embedding by incorporating fluorescent staining during preparation steps and then uses a fast, high-resolution laser-scanning multiphoton microscope to acquire images on intact tissue.

Medical Laboratory Scientists at Yale School of Medicine (New Haven, CT, USA) analyzed samples from 40 patients with a high likelihood of prostate cancer based on magnetic resonance imaging consented to investigational core biopsy. A subset of samples was used for direct comparison of physical slide preparation effects and time-tracking determination with multiphoton microscopy. Twenty samples were processed for diagnostic comparison between multilevel digital slides and subsequently produced physical slides. A reference diagnosis based on all data was established using grade groups. Level of diagnostic match and requests for immunohistochemistry were compared between physical and digital diagnoses. Immunohistochemical staining and length measurements were secondary outcomes.

Imaging of pathologist study specimens was performed in a prototype specialized ultrafast multiphoton microscope supplied by the startup company Applikate Technologies (Weston, CT, USA) that incorporates a femtosecond pulsed laser and a 0.95 numerical aperture benzyl alcohol/benzyl benzoate immersion objective. All physical tissue slides were imaged using an Aperio ScanScope (Leica Biosystems, Wetzlar, Germany) at ×40 equivalent resolution for digital storage and preparation of figures.

The scientists reported that interpretations based on direct multiphoton imaging yielded diagnoses that were at least as accurate as standard histology; cancer diagnosis correlation was 89% (51 of 57) by physical slides and 95% (53 of 56) by multiphoton microscopy. Grade-level concordance was 73% (44 of 60) by either method. Immunohistochemistry for routine prostate cancer–associated markers on these alternatively processed tissues was unaffected. Alternatively processed tissues resulted in longer measured core and cancer lengths, suggestive of improved orientation and visualization.

The authors concluded that their study demonstrates the viability of using direct digital imaging for definitive microscopic evaluation of tissue without requiring physical slide preparation for gold standard–level diagnosis. Overall, results support practical relevance of the CHiMP technique for prostate biopsy evaluation, with the potential to significantly advance prostate cancer diagnostics, and meriting continuing detailed validation as a process incorporated into clinical diagnostic practice. The study was published in the May, 2021 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Yale School of Medicine
Leica Biosystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.